Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles.
Kreusch, A., Han, S., Brinker, A., Zhou, V., Choi, H.S., He, Y., Lesley, S.A., Caldwell, J., Gu, X.J.(2005) Bioorg Med Chem Lett 15: 1475-1478
- PubMed: 15713410 
- DOI: https://doi.org/10.1016/j.bmcl.2004.12.087
- Primary Citation of Related Structures:  
1YC1, 1YC3, 1YC4 - PubMed Abstract: 
A series of dihydroxyphenylpyrazole compounds were identified as a unique class of reversible Hsp90 inhibitors. The crystal structures for two of the identified compounds complexed with the N-terminal ATP binding domain of human Hsp90alpha were determined. The dihydroxyphenyl ring of the compounds fits deeply into the adenine binding pocket with the C2 hydroxyl group forming a direct hydrogen bond with the side chain of Asp93. The pyrazole ring forms hydrogen bonds to the backbone carbonyl of Gly97, the hydroxyl group of Thr184 and to a water molecule, which is present in all of the published HSP90 structures. One of the identified compounds (G3130) demonstrated cellular activities (in Her-2 degradation and activation of Hsp70 promoter) consistent with the inhibition of cellular Hsp90 functions.
Organizational Affiliation: 
Genomics Institute of the Novartis Research Foundation (GNF), 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA.